Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Diabetes|February 28, 2015
Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in HumansJuraj Koska, Michelle Sands, Camelia Burciu, et al.
Molecular Metabolism|November 18, 2022
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systemsBin Yang, Vasily M Gelfanov, Kimberley El, et al.
Diabetologia|November 6, 2013
The role of the transcription factor ETV5 in insulin exocytosisRuth Gutierrez-Aguilar, Dong-Hoon Kim, Marina Casimir, et al.
JCI Insight|February 20, 2019
Sleeve gastrectomy rapidly enhances islet function independently of body weightJonathan D Douros, Jingjing Niu, Sophia Sdao, et al.
Annals of Internal Medicine|June 29, 2026
Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases WorkshopDavid Arterburn, Lesley H Curtis, Sengwee Toh, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 17, 2003
Total pancreatectomy and autologous islet cell transplantation as a means to treat severe chronic pancreatitisHoracio L Rodriguez Rilo, Syed A Ahmad, David D'Alessio, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 15, 2011
Ghrelin enhances olfactory sensitivity and exploratory sniffing in rodents and humansJenny Tong, Erica Mannea, Pascaline Aimé, et al.
American Heart Journal|September 27, 2023
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsStephen J Nicholls, Deepak L Bhatt, John B Buse, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
The Lancet. Diabetes & Endocrinology|May 11, 2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trialSophia Zoungas, David D'Alessio, Imre Pavo, et al.
Pageof 8